NovoCure (NASDAQ:NVCR) Trading Down 7.7% Following Insider Selling

Shares of NovoCure Limited (NASDAQ:NVCR) traded down 7.7% during trading on Friday following insider selling activity. The company traded as low as $13.19 and last traded at $13.1290. 445,392 shares were traded during trading, a decline of 80% from the average session volume of 2,190,604 shares. The stock had previously closed at $14.23.

Specifically, Chairman William F. Doyle sold 71,887 shares of NovoCure stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total value of $933,093.26. Following the sale, the chairman owned 328,397 shares in the company, valued at $4,262,593.06. This trade represents a 17.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Mukund Paravasthu sold 43,246 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $13.77, for a total value of $595,497.42. Following the transaction, the chief operating officer directly owned 72,832 shares of the company’s stock, valued at $1,002,896.64. The trade was a 37.26% decrease in their position. The SEC filing for this sale provides additional information. In related news, COO Mukund Paravasthu sold 5,377 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total transaction of $71,567.87. Following the completion of the sale, the chief operating officer directly owned 116,078 shares in the company, valued at approximately $1,544,998.18. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NVCR. Wedbush restated a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a research report on Thursday, January 15th. Evercore set a $20.00 price target on shares of NovoCure in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Finally, HC Wainwright increased their price objective on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $26.93.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Quarterly results showed an EPS beat and revenue growth (year-over-year revenue +8.2%), which supports fundamentals and was cited by analysts when updating models. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive: HC Wainwright raised its price target and several analysts maintain Buy ratings or higher targets, providing upside cases versus the current share price. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerages’ consensus rating is “Hold,” indicating limited near‑term conviction for a re‑rating; consensus target remains well above the current price, which creates a mixed signal for investors. NovoCure receives average “Hold” rating
• Neutral Sentiment: Institutional ownership is high (reported ~84.6%), which can reduce free‑float volatility but also means insider moves may attract outsized attention. Institutional holdings (MarketBeat)
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k at ~$12.98), trimming his stake by ~18% — a sizable single insider sale that the market interprets as a negative signal. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO, CEO, CFO and other insiders) executed notable sales over the same period — a pattern that amplifies negative sentiment and likely pressured the stock intraday. Aggregated filings and coverage of these insider transactions are available. Insider trades summary (MarketBeat)

NovoCure Stock Performance

The stock has a market capitalization of $1.50 billion, a PE ratio of -10.79 and a beta of 0.71. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.50 and a current ratio of 2.90. The firm’s 50 day moving average is $12.75 and its two-hundred day moving average is $12.71.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.19. The business had revenue of $174.35 million during the quarter, compared to the consensus estimate of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The company’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.61) earnings per share. As a group, research analysts predict that NovoCure Limited will post -1.3 earnings per share for the current year.

Institutional Trading of NovoCure

A number of large investors have recently made changes to their positions in the company. Empowered Funds LLC acquired a new stake in NovoCure during the 4th quarter worth $33,000. SJS Investment Consulting Inc. acquired a new stake in shares of NovoCure during the third quarter worth $41,000. Kestra Advisory Services LLC acquired a new stake in shares of NovoCure during the fourth quarter worth $49,000. Larson Financial Group LLC grew its position in NovoCure by 662.1% in the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 3,562 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in NovoCure by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after buying an additional 1,120 shares during the period. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.